

## PharmaMar and Specialized Therapeutics Asia meet in Madrid to define new agreements

- **Specialized Therapeutics Asia is PharmaMar partner in Australia, New Zealand and Southeast Asian countries for Aplidin® and lurbinectedina (Zepsyre®)**

**Madrid, April 2019.-** XX PharmaMar (MSE: PHM) and Specialized Therapeutics Asia (STA) held a meeting between presidents to agree on new steps for a licensing program and expand the ones already in place between the two companies for territories of Australia, New Zealand and Southeast Asian countries, for Aplidin® and lurbinectedina (Zepsyre®).

STA has informed that PharmaMar has opened a program with Aplidin® that has already treated more than 60 patients with multiple myeloma who have progressed to all approved therapies, and they are having very good results, with some patients receiving more than 11 cycles of Aplidin®

At this meeting, STA PharmaMar has also informed that the recent approval of Aplidin® in Australia will be extended to other licensed countries.

At this meeting the foundation has been laid for intensifying the collaboration in projects arising from new lines of research from PharmaMar.

### **Notice**

This release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer; solicitation or sale would be unlawful prior to registration or verification under the securities laws of such jurisdiction.

### **About PharmaMar**

PharmaMar is a biopharmaceutical company based in Madrid, focused on oncology and committed to research and development inspired by the sea to the discovery of molecules with antitumor activity. It is a company looking for innovative products to provide new tools to health professionals to treat cancer. His commitment to patients and research has made PharmaMar is one of the world's leading anti-tumor discovery of marine origin. PharmaMar has an important pipeline of preclinical compounds and powerful R & D program. The company develops and markets YONDELIS® in Europe and has three other compounds in clinical development for solid tumors: lurbinectedina (PM1183) and PM184 PM14. PharmaMar is a global biopharmaceutical company with presence in Germany, Italy, France, Switzerland, Belgium and the USA PharmaMar also has a majority interest in other companies: GENOMICA, first Spanish company in the field of molecular diagnostics; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi), and a chemical company, Zeltia Zelnova. For more information, visit our web site: [www.pharmamar.com](http://www.pharmamar.com)

### **About Asia Pte Ltd Specialized Therapeutics**

Specialized Therapeutics Asia Pte, Ltd. (STA) is an international biopharmaceutical company that provides pioneering and innovative people living both in Southeast Asia and in Australia and New Zealand therapies. The company is a subsidiary of Specialized Therapeutics Australia (STA) also collaborates with pharmaceutical and diagnostic companies global leaders to deliver novel, innovative health solutions that improve the lives of patients with rare diseases. ST's commitment to Asia is to develop novel therapies accessible to all patients worldwide with a broad portfolio that spans therapeutic oncology, hematology, urology and ophthalmology. For more information please visit the website [www.specialisedtherapeutics.com.au](http://www.specialisedtherapeutics.com.au).

### **For more information:**

Alfonso Ortín - Communications Manager [aortin@pharmamar.com](mailto:aortin@pharmamar.com) Mobile: + 34609493127  
Miguel Martínez-Cava-Digital Communication Manager [mmartinez-cava@pharmamar.com](mailto:mmartinez-cava@pharmamar.com) Mobile: +34 606597464  
Phone: +34 918466000



### **Investor Relations:**

Phone: +34 914444500 /+34 902 19 Oct. 00

Email: [investorrelations@pharmamar.com](mailto:investorrelations@pharmamar.com)

For more information, visit our web site: [www.pharmamar.com](http://www.pharmamar.com)